Product Description
Mechanisms of Action: ADRB1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Germany | Ireland | Italy | New Zealand | Portugal | Taiwan | Turkey
Approved Indications: None
Known Adverse Events: None
Company: Weill Medical College of Cornell University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Heart Failure, Diastolic|Heart Failure, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
K76AG064428 | P4 |
Completed |
Heart Failure, Diastolic|Heart Failure, Chronic |
2023-04-28 |
|
P19-000458 | P4 |
Completed |
Heart Failure, Diastolic|Heart Failure, Chronic |
2022-04-28 |